Disease
Heart Failure
Reduced ability of the heart to pump or fill with blood, spanning the HFrEF/HFmrEF/HFpEF ejection-fraction spectrum and acute/chronic presentations.
Coverage in progress. AssetMemo has not yet run its full census for Heart Failure with Reduced Ejection Fraction, Heart Failure with Preserved Ejection Fraction, Ischemic Heart Failure, Cardiogenic Shock in Acute Heart Failure, so the assets listed for them are not complete.
Combined attributable cost
$27.7B+
Drug spend
$9.1B+
33% of total cost is drugs
Sum of 5 indications below.
Indications
Heart Failure
$27.7B attributable cost
$1,188/patient drugs
All severities (2021-2023 NHANES cycle) · US
Heart Failure with Reduced Ejection Fraction
Market size not yet sourced
All-stage · US
Heart Failure with Preserved Ejection Fraction
Market size not yet sourced
All-stage · US
Ischemic Heart Failure
Market size not yet sourced
All-stage · US
Cardiogenic Shock in Acute Heart Failure
Market size not yet sourced
All-stage · US